[Dabrafenib (Tafinlar) therapy - effect and side effects].
Despite the continuously increasing incidence of melanoma, over decades the therapy has barely changed. However, since 2011 the "still water" moves, now with multiple medications the patient survival can be improved. Dabrafenib is the second registered BRAF kinase inhibitor. In clinical trials it resulted in 5-9 month progression-free survival (PFS). It proved to be effective in BRAF V600K mutation and also in the case of cerebral metastases. Side effects are well tolerated. The most frequent side effects are fever, skin symptoms, benign skin tumors, keratoacanthoma/squamous cell carcinoma, hyperkeratosis, weakness and joint pain.